Taxotere has been approved by the FDA and is considered a standard treatment for patients with lung cancer who have failed prior platinum-containing regimens. The main purpose of this research study is to determine if Aptosyn, when given in combination with Taxotere, will result in prolonged survival when compared to Taxotere alone. This study will also help determine tumor response rates, and the safety profile of Aptosyn in combination with Taxotere. This study has been completed and a publication is pending.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
600
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Birmingham Hematology Oncology Associates
Birmingham, Alabama, United States
Birmingham Hematology and Oncology Associates, LLC
Birmingham, Alabama, United States
Northern Arizona Hematology and Oncology Associates
Flagstaff, Arizona, United States
Hematology & Oncology Associates
Phoenix, Arizona, United States
Northern Arizona Hematology & Oncology Associates
Sedona, Arizona, United States
Arizona Clinical Research Center
Tucson, Arizona, United States
Arkansas Oncology Associates, PA
Little Rock, Arkansas, United States
Pacific Coast Hematology/Oncology Medical Group, Inc.
Fountain Valley, California, United States
California Cancer Care, Inc.
Greenbrae, California, United States
Scripps Cancer Center
San Diego, California, United States
...and 104 more locations